353 related articles for article (PubMed ID: 7967989)
1. The taxoids: paclitaxel and docetaxel.
Gelmon K
Lancet; 1994 Nov; 344(8932):1267-72. PubMed ID: 7967989
[No Abstract] [Full Text] [Related]
2. Expanding horizons: an update on the use of docetaxel in non-small cell lung, ovarian, and breast cancers.
Hortobagyi GN; Kris MG
Semin Oncol; 2002 Jun; 29(3 Suppl 12):1-3. PubMed ID: 12170444
[No Abstract] [Full Text] [Related]
3. The taxoids: paclitaxel (Taxol) and docetaxel (Taxotere).
Pazdur R; Kudelka AP; Kavanagh JJ; Cohen PR; Raber MN
Cancer Treat Rev; 1993 Oct; 19(4):351-86. PubMed ID: 8106152
[TBL] [Abstract][Full Text] [Related]
4. Taxoids: new weapons against cancer.
Nicolaou KC; Guy RK; Potier P
Sci Am; 1996 Jun; 274(6):94-8. PubMed ID: 8643952
[No Abstract] [Full Text] [Related]
5. Taxoids.
Kaye SB
Eur J Cancer; 1995; 31A(5):824-6. PubMed ID: 7640068
[No Abstract] [Full Text] [Related]
6. Use of docetaxel (Taxotere) in patients with paclitaxel (Taxol) hypersensitivity.
Moon C; Verschraegen CF; Bevers M; Freedman R; Kudelka AP; Kavanagh JJ
Anticancer Drugs; 2000 Aug; 11(7):565-8. PubMed ID: 11036959
[TBL] [Abstract][Full Text] [Related]
7. [Paclitaxel (Taxol) and docetaxel (Taxotere): results of phase II trials in monochemotherapy].
Fumoleau P; Perrocheau G; Maugard-Louboutin C; Lemevel B
Bull Cancer; 1995 Aug; 82(8):629-36. PubMed ID: 7492819
[TBL] [Abstract][Full Text] [Related]
8. Risks and benefits of taxanes in breast and ovarian cancer.
Michaud LB; Valero V; Hortobagyi G
Drug Saf; 2000 Nov; 23(5):401-28. PubMed ID: 11085347
[TBL] [Abstract][Full Text] [Related]
9. Docetaxel (Taxotere): single agent activity, development of combination treatment and reducing side-effects.
Pronk LC; Stoter G; Verweij J
Cancer Treat Rev; 1995 Sep; 21(5):463-78. PubMed ID: 8556719
[TBL] [Abstract][Full Text] [Related]
10. Docetaxel (Taxotere) in the treatment of cancer.
Burris HA
Semin Oncol; 2000 Apr; 27(2 Suppl 3):1-2. PubMed ID: 10810931
[No Abstract] [Full Text] [Related]
11. Paclitaxel (Taxol) and docetaxel (Taxotere): not simply two of a kind.
Verweij J; Clavel M; Chevalier B
Ann Oncol; 1994 Jul; 5(6):495-505. PubMed ID: 7918121
[TBL] [Abstract][Full Text] [Related]
12. Docetaxel as an alternative to paclitaxel after acute hypersensitivity reactions.
Bernstein BJ
Ann Pharmacother; 2000 Nov; 34(11):1332-5. PubMed ID: 11098349
[TBL] [Abstract][Full Text] [Related]
13. Docetaxel: current status and future prospects.
Eisenhauer E
J Clin Oncol; 1995 Dec; 13(12):2865-8. PubMed ID: 8523048
[No Abstract] [Full Text] [Related]
14. The taxanes: an update.
Crown J; O'Leary M
Lancet; 2000 Apr; 355(9210):1176-8. PubMed ID: 10791395
[TBL] [Abstract][Full Text] [Related]
15. Paclitaxel and docetaxel in breast and ovarian cancer.
Drug Ther Bull; 1997 Jun; 35(6):43-6. PubMed ID: 9282422
[TBL] [Abstract][Full Text] [Related]
16. Docetaxel.
Cortes JE; Pazdur R
J Clin Oncol; 1995 Oct; 13(10):2643-55. PubMed ID: 7595719
[TBL] [Abstract][Full Text] [Related]
17. [Development of a new tubulin-interacting agent, docetaxel (taxotere) in Japan].
Tsukagoshi S
Gan To Kagaku Ryoho; 1997 Jul; 24(9):1167-74. PubMed ID: 9239173
[TBL] [Abstract][Full Text] [Related]
18. Taxing the taxanes: overused or undersold?
Miller M
J Natl Cancer Inst; 1999 Dec; 91(24):2077-8. PubMed ID: 10601377
[No Abstract] [Full Text] [Related]
19. Successful docetaxel rechallenge with cromoglycate after major sensitivity reactions.
Westermann AM; ten Bokkel Huinink WW; Rodenhuis S
Ann Oncol; 1996 Jan; 7(1):104. PubMed ID: 9081381
[No Abstract] [Full Text] [Related]
20. The taxoids. Comparative clinical pharmacology and therapeutic potential.
Eisenhauer EA; Vermorken JB
Drugs; 1998 Jan; 55(1):5-30. PubMed ID: 9463787
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
